Program

Hope on the horizon? Exploring PACAP's role in migraine

08:30 - 08:45

Unveiling PACAP's role in migraine: Evidence from human provocation studies

08:45 - 09:00

Decoding PACAP signalling: Splice variants, pathways, and designer drugs

09:00 - 09:15

Can PACAP activate meningeal nociceptors?

09:15 - 09:30

PACAP vs. CGRP: Unveiling migraine mechanisms through mouse models

Decoding treatment success: unveiling biomarkers for migraine treatment

09:30 - 09:45

Profiling non-responders and super-responders to anti-CGRP treatment

09:45 - 10:00

Clinical features and biomarkers predicting treatment response in migraine

10:00 - 10:15

Role of central sensitisation and interictal allodynia

10:15 - 10:30

Molecular biomarkers and migraine treatment response

Break

Opening Ceremony and Presidential Symposium

IHS Special Lecture

Break

Artificial Intelligence: Regulation and monitory algorithm that reduces risk?

09:00 - 09:17

Connecting emotions, brain, and behaviour with wearables in migraine and chronic pain patients

09:17 - 09:34

Patient data to give the right patient the right treatment at the right time

09:34 - 09:51

The implementation of AI in the migraine field – from neural networks to networked care

09:51 - 10:00

Discussion

– Migraine-related cognitive functions – real or not real: Evidence and description, pathophysiology, implications of treatment

10:00 - 10:15

Deciphering the mechanisms: Pathophysiology of migraine-related cognitive dysfunction

10:15 - 10:30

Cognitive impairments in primary and secondary headache disorders

10:30 - 10:45

Migraine and cognitive decline

10:45 - 11:00

Altered cognition-related brain activity and interactions with acute pain

Break

IHS Annual General Meeting and Advisory Council

Sex role in response to acute and preventive treatment of migraine: Is the evidence strong enough to exclude males?

15:00 - 15:15

Sex differences in response to triptans

15:15 - 15:30

Pain behaviours to CGRP and other neuropeptides – sex differences?

15:30 - 15:45

Evaluation of outcomes of CGRP-targeting therapies for acute and preventive migraine treatment based on patient sex

15:45 - 16:00

Is there a gender difference in the response to onabotulinumtoxinA or CGRP inhibitors in chronic migraine?

Break

Do genetic variants determine endophenotypes and comorbidities of migraine?

13:00 - 13:15

Rare variants with large effects provide functional insights into the pathology of migraine subtype

13:15 - 13:30

Shared genetics and causal relationships between migraine and its comorbidities

13:30 - 13:45

Genetic susceptibility of migraine endophenotypes across ethnicities

13:45 - 14:00

Mapping out neurons that contribute to headache (USA)

Primary care approach to headache patients

14:00 - 14:15

Migraine multidisciplinary approach in family medicine

14:15 - 14:30

Exclusion of important life-threatening causes of headache

14:30 - 14:45

Managing primary headache disorders in a primary headache care setting

14:45 - 15:00

Discussion

The complex relationship between circadian rhythm and cluster headache

16:15 - 16:30

Circadian features of headache disorders – can I explain why?

16:30 - 16:45

Genetics and chronobiology of cluster headache

16:45 - 17:00

Chronobiology of cluster headache attacks – my proposed explanation

17:00 - 17:15

Discussion

Facial representation of primary headache

13:00 - 13:15

Facial trigeminal autonomic cephalalgias (TACs)

13:15 - 13:30

Low face migraine

13:30 - 13:45

Facial tension type headache

13:45 - 14:00

Optimising combined treatment for migraine and temporomandibular disease.

Is migraine with aura a distinct disorder or a symptom of migraine?

14:00 - 14:15

Migraine with and without aura are distinct disorders

14:15 - 14:30

CSD provides a common therapeutic target for widely prescribed migraine prophylactic drugs and neuromodulation devices

14:30 - 14:45

Brain imaging in migraine with and without aura: Similarities and differences

14:45 - 15:00

Discussion

(LTB & IHS JOINT MEETING): Global, regional, and national epidemiology and burden of headache: Unravelling the past and envisioning the future

16:15 - 16:30

Global disparities in migraine care: A call for universal access to diagnosis and treatment

16:30 - 16:45

Regional variations in headache burden

16:45 - 17:00

Migraine service quality in the global perspective of Lifting The Burden

17:00 - 17:15

Discussion

What can headaches in children and adolescents teach us about caring for adults?

13:00 - 13:15

The biology and genetics of childhood and adolescent migraine: Why the prevalence is similar in childhood but different in adolescence

13:15 - 13:30

Mitochondrial role in paediatric migraine pathophysiology

13:30 - 13:45

The role of sex hormones in migraine attack initiation: Can we explain onset of migraine attacks during puberty?

13:45 - 14:00

Impact of co-morbidity, resilience, and vulnerability on childhood and adolescent headaches

Is early treatment important in the approach to episodic and chronic migraine?

14:00 - 14:15

Treating the attack during the prodromal phase: Gain or waste?

14:15 - 14:30

Early prevention: Disease prevention or prevention of disease progression?

14:30 - 14:45

What do the guidelines say?

14:45 - 15:00

Discussion

Navigating the intersections: Headaches, epilepsy, and shared pathways

16:15 - 16:30

Migraine – a borderland disease to epilepsy: Near it but not of it

16:30 - 16:45

Pathophysiology of ictal and post-ictal headache

16:45 - 17:00

Migraine and idiopathic epilepsies comorbidity

17:00 - 17:15

Migraine and epilepsy: From bench to bedside

IHS grants 1

Deciphering idiopathic intracranial pressure: Is it a spinal fluid regulation disorder or a metabolic disease causing dysregulation of spinal fluid production?

14:00 - 14:15

Metabolic perspectives in idiopathic intracranial hypertension

14:15 - 14:30

Novel therapeutic approaches and efficacy of epidural blood patching or surgery in spontaneous intracranial hypotension

14:30 - 14:45

Proposing management strategies tailored to addressing intracranial hypotension

14:45 - 15:00

Discussion

Where does combining acute and preventive treatment fit?

16:15 - 16:30

Scientific rationale for polytherapy

16:30 - 16:45

Acute treatment of migraine: When one drug is not enough

16:45 - 17:00

Prophylactic treatment of migraine: When one drug is not enough

17:00 - 17:15

Experiences with dual therapy with onabotulinumtoxinA and CGRP antibodies: Real world evidence data

Cephalalgia Award Lectures

Controversies in migraine: The prodromal phase

17:00 - 17:15

Cracking the code: Inconsistencies and issues in assessing the migraine prodrome

17:15 - 17:30

Different kinds of migraine triggers are reported in different parts of the world

17:30 - 17:45

The hypothalamus: Conductor of the migraine prodrome

17:45 - 18:00

Is the hypothalamus to blame? Rethinking its role in the migraine prodrome

Trainees Tournament

Cluster headache and insights for the role of anti-CGRPs in acute and prophylactic treatment

09:00 - 09:15

Understanding the pathogenesis of cluster headache in the CGRP era: Where are we?

09:15 - 09:30

Do pathophysiological differences exist between episodic and chronic cluster headache?

09:30 - 09:45

Clinical response prediction of approved anti-CGRP in the prevention of cluster headache and what is next

09:45 - 10:00

Discussion

Break

Oral communications 1

Parallels and divergences in visual snow syndrome (VSS) and migraine

14:30 - 14:45

VSS is a form of migraine aura–overlapping clinical features, neurophysiology, and neuroimaging

14:45 - 15:00

VSS is a distinct clinical entity: What we learned from neuro-ophthalmological and behavioural research

15:00 - 15:15

Visual snow vs. migraine aura

15:15 - 15:30

Debate summary and novel insights into the syndrome

Break

Late-Breaking Abstracts (Basic)

- Migraine aura – a not-so-easy-to-detect condition

09:00 - 09:15

Decoding the aura table: Unveiling visual disturbances and perception in migraine auras

09:15 - 09:30

Beyond the scan: Exploring neuroimaging and the quest for objective documentation of migraine aura phenomena

09:30 - 09:45

Initiation and propagation of spreading depolarisation: Considerations for migraine

09:45 - 10:00

Discussion

Break

Oral Communications 2

Migraine in pregnancy and lactation

14:30 - 14:45

Sex and hormonal influences on migraine pain – the science

14:45 - 15:00

Prescribing for pregnancy: Managing chronic headache and migraine

15:00 - 15:15

CGRP, onabotulinumtoxinA, and others. Are they safe?

15:15 - 15:30

Addressing migraine in the breastfeeding period: Practical approaches for primary care providers

Break

Late-Breaking Abstracts (Clinical)

Migraine treatment in children and adolescents: Should we rewrite our guidelines?

09:00 - 09:15

Update on pharmacological options currently available for the treatment of migraine in children and adolescents

09:15 - 09:30

Does controlling migraine improve interictal cognition in children and adolescents? Does more need to be done?

09:30 - 09:45

What are the key messages for the non-pharmacological approach of migraine in children and adolescents?

09:45 - 10:00

Discussion

Break

Oral Communications 3

The surgeon's role in managing trigeminal neuropathic pain

14:30 - 14:45

Demystifying trigeminal neuropathic pain in the face and mouth - guidelines on diagnosis, treatment, and follow-up care

14:45 - 15:00

The science behind neuromodulation procedures for trigeminal neuralgia

15:00 - 15:10

The role of tumours in headaches and neuralgias – the perspective from neurosurgery

15:10 - 15:30

Discussion

Break

Late-Breaking Industry Abstracts

Update on neuromodulation

09:00 - 09:15

Transcranial direct current stimulation (tDCS)

09:15 - 09:30

Transcranial magnetic stimulation (TMS)

09:30 - 09:45

Peripheral nerve stimulation

09:45 - 10:00

Discussion

Break

IHS grants 2

Break

Headache management in low- and middle-income countries (LMIC): realities, challenges & solutions

14:30 - 14:45

Telemedicine as a solution for headaches in LMIC countries

14:45 - 15:00

Telemedicine in headache education

15:00 - 15:15

How can better education improve the management of headaches in LMIC countries

15:15 - 15:30

Discussion

Break

Update on neurotoxins

16:00 - 16:20

Non-paralytic botulinum toxins for the treatment of headaches and pain

16:20 - 16:40

Anti-nociceptive activities of novel long-acting SNARE-inactivating biotherapeutics

16:40 - 17:00

Chimeric toxin-based therapeutics